Medicus Pharma gets UAE approval for Phase 2a p... Pluang
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix Quiver Quantitative
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Phase 2a Endometriosis Study of Teverelix quiverquant.com
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer Endpoints News
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix Proactive financial news
To investigate whether the etiology of diminished ovarian reserve (DOR) independently influences outcomes of assisted reproductive technology (ART).
Uterine artery embolization (UAE) is a minimally invasive therapeutic option for adenomyosis (AM). However, its clinical effectiveness in patients with comorbid gynecologic disorders remains unclear. This study aimed to evaluate …
Cardiothoracic involvement by obstetric and gynecologic pathologic conditions creates a broad spectrum of clinical and radiologic manifestations, ranging from mild to critical. The authors describe the unique and often unrecognized …
To investigate, using transvaginal ultrasound imaging, the overlap between polycystic ovarian morphology (PCOM) and endometriosis, and to explore demographic and clinical factors associated with their coexistence across endometriosis phenotypes.
Accurate and standardised characterisation of endometriosis extent is essential for patient counselling regarding pain and fertility outcomes, surgical planning, multidisciplinary communication, and clinical research. The Enzian classification has been applied …